Resmed SEC Filings

ResMed Inc. (RMD) reported a change in director ownership through a Form 4 filing. Director Ronald Taylor received an award of 1,073 shares of ResMed common stock on 11/20/2025 at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 24,771 shares directly.

The shares awarded are in the form of Restricted Stock Units (RSUs). These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with the company’s long-term performance and shareholder interests.

ResMed Inc. (RMD) Chief Financial Officer Brett Sandercock reported an equity award vesting. On 11/20/2025, he acquired 2,710 shares of ResMed common stock at a price of $0 per share, reflecting the earning of performance-based restricted stock units originally granted on 11/16/2022. The compensation and leadership development committee certified that the required performance metrics were met, which triggered the share delivery.

Following this transaction, Sandercock beneficially owns 88,495 shares of ResMed common stock in direct ownership. This filing is a routine disclosure of insider equity compensation vesting and does not indicate an open-market purchase or sale.

ResMed Inc. (RMD) Chairman and CEO Michael J. Farrell reported routine equity compensation activity. On 11/20/2025, he acquired 13,551 shares of ResMed common stock at $0, following the earning of performance-based restricted stock units that were granted on November 16, 2022 and certified as earned by the compensation and leadership development committee.

On the same date, 7,297 shares were disposed of at $0 to ResMed to cover tax withholding on the vesting. After these transactions, Farrell beneficially owned 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

ResMed Inc. (RMD) reported an insider equity award for director Christopher DelOrefice. On 11/20/2025, he acquired 1,073 shares of ResMed common stock at a price of $0, reported as an award of restricted stock units. After this transaction, he beneficially owns 2,423 shares directly.

The filing notes that these restricted stock units (RSUs) vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the award to continued board service.

ResMed Inc. director equity grant reported on Form 4. Director Jan De Witte reported receiving 1,073 shares of ResMed common stock in the form of restricted stock units on 11/20/2025 at a price of $0 per share. After this grant, De Witte beneficially owns 6,316 shares directly. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning director compensation with the company’s long‑term performance.

ResMed Inc. (RMD) director Peter C. Farrell reported an equity award under a director compensation program. On 11/20/2025, he acquired 536 shares of ResMed common stock at a stated price of $0, reported as an acquisition of non-derivative securities. Following this transaction, he beneficially owned 70,773 shares held directly.

The filing explains that these shares were awarded in the form of Restricted Stock Units (RSUs). The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.

ResMed Inc. (RMD) reported insider information for director Richard Sulpizio on a Form 4. Following the reported activity, he beneficially owned 17,796 shares of ResMed common stock in direct ownership. The filing also notes that Sulpizio ceased to serve as a director at the conclusion of ResMed’s 2025 annual meeting of stockholders held on November 19, 2025, marking his departure from the company’s board.

ResMed Inc. is registering an additional 3,000,000 shares of its common stock, par value $0.004, for issuance under the ResMed Inc. 2018 Employee Stock Purchase Plan. This filing uses the streamlined General Instruction E to Form S-8 and incorporates prior S-8 registrations from 2004, 2013 and 2020 by reference. ResMed also incorporates its latest Form 10-K for the year ended June 30, 2025, its Form 10-Q for the quarter ended September 30, 2025, several recent Form 8-Ks, and the description of its common stock. The document restates the company’s indemnification protections for directors and officers under Delaware law, its charter and bylaws, and confirms that key executives and directors have signed the registration and granted powers of attorney.

ResMed Inc. reported the results of its 2025 annual meeting of stockholders. Director Richard Sulpizio did not seek re-election, and his term ended at the close of the meeting. The board then reduced its size from twelve to eleven members, with stockholders electing eleven directors to serve until the 2026 annual meeting.

Stockholders approved several key proposals. They ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers. They also approved an amendment and restatement of the 2009 Incentive Award Plan, increasing the shares reserved for issuance by 2,400,000, eliminating the plan’s fixed term, and authorizing incentive stock options. In addition, they approved an amendment and restatement of the 2018 Employee Stock Purchase Plan, increasing its share reserve by 3,000,000, removing its fixed term, and providing for tax-qualified purchase rights under Section 423 of the Internal Revenue Code.